MedTrace Logo

Endurance Performance at Altitude

NCT03710369 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-10-18

No results posted yet for this study

Summary

The degree to which endurance exercise performance is diminished in acute hypoxia is variable and appears to be the result of several different physiological processes, however this research focuses on hypoxic pulmonary vasoconstriction (HPV). Sildenafil, a pulmonary vasodilator, has been used with mixed results to improve athletic performance in hypoxia. Because sildenafil has been shown to reduce HPV in some individuals, we believe that its effectiveness is closely related to the magnitude of the HPV response and the degree that individual exercise performance declines in hypoxia. This research will investigate the relationship between sildenafil, HPV, and exercise performance.

Conditions

  • Altitude
  • Hypoxia
  • Sildenafil
  • Exercise

Interventions

DRUG

Placebo

The placebo pill was compounded by McDonalds Pharmacy.

DRUG

Sildenafil

Sildenafil from Pfizer, compounded by McDonalds Pharmacy.

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Eric Carter, MSc · UBC

  • Michael Koehle, MD, PhD · UBC

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-11-01
Primary Completion
2018-10-01
Completion
2018-10-02

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03710369 on ClinicalTrials.gov